The aberrant Trop-2 overexpression is associated in several solid tumors including colorectal, lung cancer, and breast cancers.
Global TROP2 Antibody Market Clinical Trials Insight 2026 Report Findings:
- Research Methodology
- Global & Regional Market Analysis
- Global TROP2 Antibody Market Opportunity Assessment
- Market and Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 1 Drugs
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Download Report
Trop-2 (also called epithelial glycoprotein-1, gastrointestinal antigen 733-1, membrane component surface marker-1, and tumor-associated calcium signal transducer-2) has recently been identified as a potential target for the cancer. The aberrant Trop-2 overexpression is associated in several solid tumors including colorectal, lung cancer, and breast cancers. Recently in 2020, Trodelvy developed by Gilead Science has gained entry into the market. The drug belongs to the class of antibody drug conjugate and is directed towards trophoblast cell-surface antigen 2 (TROP2) and has been indicated for the management for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
Trodelvy is an antibody drug conjugate (ADC) composed by a humanized RS7 antibody targeting Trop-2 linked with SN38, a topoisomerase I inhibitor, the active metabolite of irinotecan with 100–1000-fold higher potency with respect to the parent drug. Apart from triple negative breast cancer, researchers are also evaluating the role of drug in targeting other cancers including hormone receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, metastatic non-small cell lung cancer, endometrial carcinoma, urothelial cancer, glioblastoma and hepatocellular carcinoma.
Besides Trodelvy, several other Trop-2 targeting drugs are being developed and evaluated in preclinical and clinical stages. For instance, Daiichi Sankyo has developed datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd ADC for metastatic triple negative breast cancer. Furthermore, the development of Trop-2 targeting therapies also involves nanoparticles conjugated with anti-TROP2 antibody. Several preclinical studies have demonstrated that nanoparticles are actively taken by Trop2-expressing TNBC cell lines and exhibit higher toxicity than control nanoparticles lacking the disulfide bond or anti-Trop2 antibody.
The encouraging response of Trodelvy in the market has further surged the government initiatives to boost the clinical trials in this sector. For instance, Everest Medicines have recently announced that Ministry of Food and Drug Safety (MFDS) of South Korea accepted its New Drug Application (NDA) for Sacituzumab Govitecan for TNBC. The MFDS in South Korea previously granted Fast Track Designation and Orphan Drug Designation to SG for the treatment of mTNBC in April 2021. Apart from this, Sorrento Therapeutics has announced that its partner Escugen Biotechnology and its subsidiary Levena Biopharma have received clearance to begin clinical trials with anti-TROP2 antibody drug conjugate for multiple solid tumors.
Currently, the global TROP2 inhibitor market is present at blooming stage owing to the approval of one drug. However, it is expected that the coming years will witness tremendous growth rates in the market which is mainly due to increase in prevalence of cancer and the unmet need for the targeted therapy. Apart from this, the increase in awareness about the availability of drugs, upcoming new drugs approval, and rise in government initiatives will also boost the growth of market. US is anticipated to have a dominant share in the market which is mainly attributed to rise in awareness about new drugs for the treatment, availability of all major companies in the region, the introduction of new drugs, and high prevalence of cancer in the region. Apart from this, US government has also developed favorable reimbursement policy for Trodelvy which further enhances the uptake of the in the region.
Our report provides insight into the patent, price, dosage, and sale analysis of currently approved Trop2 inhibitor. Further, the reports also give comprehensive analysis on the ongoing clinical trials in Trop2 inhibitor market and other trends in the global market. Keeping in mind the various driver and challenges, the future outlook of Trop2 inhibitors has also been analyzed in the report. Furthermore, the key players mentioned in the report are Arius Research, AstraZeneca, Gilead Sciences, Daiichi Sankyo, Janux Therapy, Pfizer, and Shanghai Junshi Biosciences.
Contact:
Neeraj Chawla
Research head
Kuick Research
+91-9810410366